Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03976102
Title Compare the Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (FLINTER)
Acronym FLINTER
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Dr. Reddy's Laboratories Limited
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
The Oncology Institute of Hope and Innovation Whittier California 90602 United States Details
American Oncology Partners of Maryland Bethesda Maryland 20817 United States Details
University of Tennessee Medical Center - Cancer Institute Knoxville Tennessee 37920 United States Details
Gulf coast Oncology Associates, PA Houston Texas 77089 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field